内容紹介
Combination of Targeted Therapy and Immunotherapy for Cancer
Summary
Targeted therapies and immunotherapies attack tumor cells through different mechanisms. In addition, these therapies exhibit quick and delayed effects, respectively, and therefore, these therapies are complementary. Furthermore, targeted therapies may enhance the function of immune cells, and therefore, both the therapies are expected to have a synergistic effect. Antitumor immune responses comprise several steps including dendritic cell activation, T cell activation, and dampening tumor-induced immunosuppression; targeted drugs that work at each step have been reported. Clinical trials of rational combinations of both therapies, while avoiding severe adverse events, will greatly advance cancer treatments in the near future.
要旨
分子標的療法と免疫療法は作用機序が異なること,前者は即効性,後者は遅効性であることから,互いに補い合い併用効果が期待できる。また,分子標的薬は免疫細胞にも作用し得ることから,両療法の相乗効果も期待できる。抗腫瘍免疫反応は複数のステップからなり,これらの各ステップに作用する分子標的薬が報告されている。今後,分子標的療法と免疫療法の合理的な併用を行うとともに,併用によって新たに起こる副作用に注意しながら臨床試験を進めることにより,がん治療が格段に進歩することが期待される。
目次
Summary
Targeted therapies and immunotherapies attack tumor cells through different mechanisms. In addition, these therapies exhibit quick and delayed effects, respectively, and therefore, these therapies are complementary. Furthermore, targeted therapies may enhance the function of immune cells, and therefore, both the therapies are expected to have a synergistic effect. Antitumor immune responses comprise several steps including dendritic cell activation, T cell activation, and dampening tumor-induced immunosuppression; targeted drugs that work at each step have been reported. Clinical trials of rational combinations of both therapies, while avoiding severe adverse events, will greatly advance cancer treatments in the near future.
要旨
分子標的療法と免疫療法は作用機序が異なること,前者は即効性,後者は遅効性であることから,互いに補い合い併用効果が期待できる。また,分子標的薬は免疫細胞にも作用し得ることから,両療法の相乗効果も期待できる。抗腫瘍免疫反応は複数のステップからなり,これらの各ステップに作用する分子標的薬が報告されている。今後,分子標的療法と免疫療法の合理的な併用を行うとともに,併用によって新たに起こる副作用に注意しながら臨床試験を進めることにより,がん治療が格段に進歩することが期待される。